問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2023-09-19

林恕民Lin, Shu-Min
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -3 個月

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林恕民

List

46Cases

2026-01-02 - 2030-01-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting6Sites

2025-04-01 - 2027-11-30

Phase III

Active
An interventional, phase 3, double-blind, 2-arm trial investigated the efficacy and safety of oral ibuzatarlevil compared to placebo in non-hospitalized symptomatic adults and adolescents with COVID-19 at high risk of developing severe illness.

  • Condition/Disease

    Novel Coronavirus Disease

  • Test Drug

    PF-07817883(IBUZATRELVIR)

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2030-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2025-01-31 - 2028-01-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2026-01-29 - 2031-11-15

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2005-12-01 - 2007-12-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2005-12-01 - 2006-12-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2024-01-22 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2025-06-01 - 2028-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB